Tasso Announces Next Generation Technology for Patient-Centric Dried Blood Spot Sample Collection

New collection system modernizes the dried blood spot patient experience for clinical trials and has the potential to improve trial timelines, speed drug development

SEATTLE--(BUSINESS WIRE)--Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the launch of its next generation technology for dried blood spot (DBS) sample collection. The novel collection system combines Tasso’s new Tile™-T20 dried whole blood cartridge with a Tasso™ Mini device, enabling the precise, convenient collection of DBS samples for clinical trials and sports anti-doping testing.

Tasso’s new collection system provides advantages over legacy DBS methods, improving and accelerating the clinical trial process. Tile-T20 is the first DBS collection cartridge designed specifically for use with patient-centric blood lancets. Tile-T20 collects four precise, volumetrically-controlled blood samples that meet the needs of quantitative endpoints or drug concentration measurements. It is compatible with any of Tasso’s virtually painless, FDA-cleared and CE Marked blood collection devices, including Tasso Mini and Tasso+®.

Tasso Mini is the latest device in Tasso’s signature line of patient-centric blood lancets, providing a gentle collection experience ideal for use with sensitive populations or for applications that may require more frequent blood draws. The Tasso Mini device is FDA Class II Lancet 510(k)-cleared and CE Marked.

“Dried blood samples offer many advantages for clinical trials and remote applications, but collection methods have long been a burden on patients, relying on painful finger sticks and messy blood spotting to obtain samples,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Our next generation dried blood collection systems enable a better patient experience alongside new process improvements.”

“Access to clinic sites can be difficult for many patients, especially for those without reliable transportation or living in rural areas. Unfortunately, access challenges often lead to recruitment and retention issues, ultimately delaying clinical trial timelines,” said Erwin Berthier, PhD, CTO and Co-Founder of Tasso. “This new technology has the potential to improve trial timelines and speed new therapies to patients in need.”

To learn more about Tasso’s dried blood collection solutions, please visit www.tassoinc.com/dried-blood.

About Tasso

Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.